Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P.Morgan Week 2023 in San Francisco in January. Elpiscience’s Co-Founder and CEO Darren Ji will also be sharing his perspective on the BioPharma Business in the Asia Pacific Region: Huge Markets, Great Opportunities panel at the conference.
“We are excited to bring to the world our novel immunotherapies, including our first-in-class anti-CD39/TGF-β bispecific antibody 欧洲杯买球网游戏 potentially for PD-(L)1 resistant patient population, a highly differentiated anti-LILRB2 antibody 欧洲杯买球网棋牌, and a pan-acting anti-SIPRα antibody ES004. We look forward to collaborating with pharmaceutical partners to advance our innovative drug candidates to benefit cancer patients worldwide,” said Darren Ji, Co-Founder, and CEO of Elpiscience.
Event Schedules:
Elpiscience’s presentation
Darren Ji, Co-Founder and CEO of Elpiscience
Date and Time: 9 January 2023, 14:30 – 14:45 PST
Location: Hilton Union Square, Franciscan C (Ballroom Level), San Francisco CA
Panel: BioPharma Business in the Asia Pacific Region: Huge Markets, Great Opportunities
Darren Ji, Co-Founder and CEO of Elpiscience
Date and Time: 10 January 2023, 9:00 – 10:00 PST
Location: Hilton Union Square, Imperial Ballroom, San Francisco CA
Elpiscience’s team is participating in partnering system and welcomes the opportunity to meet with potential partners. For meeting appointments, registered attendees can send a request through Biotech Showcase Partnering Platform, and or by contacting Elpiscience directly at BD@elpiscience.com.
- Prev:Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody 欧洲杯买球网游戏
- Next:Elpiscience Announces China CDE IND Clearance of 欧洲杯买球网游戏, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
Corporate Communications:
PR@elpiscience.com
Partnering:
BD@elpiscience.com
